Detail akcie Labcorp Hldgs online

Business Summary: Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Labcorp Holdings Inc revenues increased 5% to $3.35B. Net income decreased 7% to $212.8M. Revenues reflect DX segment increase of 6% to $2.63B, BLS segment increase of 1% to $721.3M. Net income was offset by General corporate segment loss increase of 6% to $208.4M. Dividend per share remained flat at $0.72. Basic Earnings per Share excluding Extraordinary Items decreased from $2.71 to $2.55.